• Image attribution tooltip
    Brian Tucker / BioPharma Dive

    5 questions facing biotech M&A in 2022

    Analysts expect that deal engines are ready to start firing again following the recent quiet period. Still, uncertainty remains about how biopharma acquisitions could play out in the coming months.

    By Jan. 12, 2022
  • Image attribution tooltip
    Danielle Ternes / BioPharma Dive

    JPM22: M&A anxiety, Roche's comeback plan and Vir's omicron moment

    Pharma executives fielded many questions about their dealmaking intentions on the conference's second day, while Roche outlined its plan to compete against Merck and Bristol Myers in cancer immunotherapy.

    By , Jan. 11, 2022
  • Image attribution tooltip
    Dan Kitwood via Getty Images

    Pfizer expands into gene editing with Beam research deal

    Pfizer's work with mRNA vaccines led it to explore other applications of the technology, resulting in a multiyear partnership with the high-profile biotech Beam Therapeutics on gene editing treatments for rare diseases.

    By Jan. 10, 2022
  • Lilly pours more money into genetic treatments for neurological diseases

    For $50 million, Lilly has secured rights to a technology that's meant to transport nucleic acid therapies in a way that's more targeted and better tolerated than other methods.

    By Jan. 6, 2022
  • Image attribution tooltip
    Permission granted by Biogen

    Biogen brings in a successor to Spinraza

    The company spent $60 million to secure global rights to an experimental drug developed by Ionis Pharmaceuticals to treat spinal muscular atrophy.

    By Jan. 4, 2022
  • Image attribution tooltip

    Novartis ups investment in gene therapy for the eye with $800M buyout

    The deal for Gyroscope Therapeutics, worth up to $1.5 billion, gives the Swiss pharma access to a treatment for a type of age-related blindness as well as new means of delivering drugs into the eye.

    By Dec. 22, 2021
  • Image attribution tooltip
    Courtesy of Sanofi

    Sanofi to buy cancer immunotherapy biotech for $1B

    The French drugmaker is interested in Amunix Pharmaceuticals' technology, which could allow for more precise delivery of biologic drugs into cancerous tissue.

    By Dec. 21, 2021
  • Image attribution tooltip
    Permission granted by Bristol-Myers Squibb

    Bristol Myers returns to Immatics for a dual-targeting cancer drug

    The pharma has expanded an alliance with a German biotech by paying $150 million for a drug candidate that executives hope can have "cell therapy-like efficacy" for solid tumors. 

    By Dec. 14, 2021
  • Image attribution tooltip
    Dan Kitwood via Getty Images

    Arena, completing its turnaround, sells to Pfizer for nearly $7 billion

    Pfizer will pay $100 per share to acquire Arena and the portfolio of inflammatory disease medicines it developed in the wake of a disappointing drug launch.

    By Updated Dec. 13, 2021
  • Sobi buyout breaks down

    Three months after proposing a roughly $8 billion acquisition of Sobi, the investment firms Advent International and GIC have withdrawn their offer.

    By Dec. 3, 2021
  • Image attribution tooltip

    Novartis pays $150M for access to UCB's Parkinson's drug

    UCB's experimental pill is one of the most advanced projects that's aimed at blocking accumulation of an abnormal protein in patients' brains.

    By Dec. 2, 2021
  • Image attribution tooltip
    Warren Little via Getty Images

    GSK sets sights on brain diseases through Oxford partnership

    Equipped with $40 million in funding, a new institute from GSK and Oxford will initially focus on developing treatments for Alzheimer's, Parkinson's, ALS and other neurological conditions.

    By Dec. 2, 2021
  • Image attribution tooltip
    SciePro via Getty Images

    Blueprint, taking aim at larger drugmakers, becomes a biotech buyer

    A $250 million acquisition of startup Lengo Therapeutics has given Blueprint a lung cancer drug that could compete with medicines from Takeda and J&J.

    By Nov. 29, 2021
  • GSK dives into NASH, RNA interference with Arrowhead deal

    GSK has secured rights to a genetic medicine in early-stage human testing for NASH, a disease thought to affect millions of people that has proven to be a tough target for drugmakers. 

    By , Nov. 23, 2021
  • Image attribution tooltip
    Getty Images

    Neurocrine stocks up on a biotech's psychiatric drugs

    A new deal with Sosei Heptares hands Neurocrine a "broad portfolio" of drugs for schizophrenia, dementia and other neuropsychiatric disorders.

    By Nov. 22, 2021
  • Image attribution tooltip
    Permission granted by Gilead Sciences

    Gilead pays up to retain rights to Arcus cancer drugs

    The biotech will pay $725 million to opt into rights on four experimental medicines developed by Arcus, including ones that could challenge Merck's Keytruda in lung cancer.

    By Nov. 18, 2021
  • Image attribution tooltip
    Novo Nordisk

    Novo to acquire Dicerna for more than $3B amid RNA drug resurgence

    The acquisition would give Novo Nordisk ownership of one of the oldest and largest developers of RNA interference drugs, along with a web of potential royalty streams. 

    By Updated Nov. 18, 2021
  • Image attribution tooltip
    Permission granted by Biohaven Pharmaceuticals

    Pfizer buys into Biohaven's fast-selling migraine medicine

    The pharmaceutical giant will pay Biohaven $500 million for ex-U.S. rights to rimegepant — a sizable licensing deal, though not the buyout that some of the biotech's investors appeared to be hoping for.

    By Nov. 9, 2021
  • Image attribution tooltip
    Courtesy of Sanofi

    Eye-focused gene therapy startup gets $60M cash infusion from Sanofi

    Shortly after postponing a $135 million IPO, Gyroscope has found another way to back a treatment for a disease that's become a top target of multiple drugmakers.  

    By Nov. 8, 2021
  • Image attribution tooltip

    Novartis to sell long-held stake in Roche for nearly $21B

    Novartis, which paid around $5 billion for its shares two decades ago, says it will gain about $14 billion from its sale and use the proceeds to further its current strategy.

    By Nov. 4, 2021
  • Image attribution tooltip
    Getty / Edited by BioPharma Dive

    Cystic fibrosis group partners with Moderna founder to find better, potentially curative treatments

    With an initial investment of $20 million, the collaboration will use technologies from various Flagship-backed companies to discover and develop new therapies for the disease.

    By Nov. 3, 2021
  • Image attribution tooltip
    Courtesy of Intellia Therapeutics

    Intellia looks to eye diseases in latest deal

    The gene editing company will take a 10% stake in SparingVision, a young biotech that will use Intellia's CRISPR technology to develop treatments for up to three ocular targets.

    By Oct. 13, 2021
  • Image attribution tooltip
    Getty Images

    Takeda takes aim at a biotech's gene therapy work

    For an upfront payment of $45 million, Takeda gains access to as many as eight programs from Poseida Therapeutics and a potential method of delivering gene therapies without the help of viruses.

    By Oct. 12, 2021
  • Image attribution tooltip
    Elizabeth Regan / Industry Dive

    Adamas, Flexion sell for $825M combined as biotech's dealmaking pace picks up

    After lagging for months, M&A has accelerated over the past five weeks. The latest evidence comes from two deals based largely on future drug sales.

    By Oct. 11, 2021
  • Image attribution tooltip

    Otsuka partners with Sunovion, Sumitomo in neurology drug pact

    Sunovion will receive $270 million from Otsuka, and as much as $620 million more, in exchange for splitting rights to four experimental psychiatric drugs.

    By Kristin Jensen • Sept. 30, 2021